| Ytd | -31.55% | |
| 1y | -42.04% |
| Open | 0.76 | Prev Close | 0.77 | Low | 0.76 | High | 0.81 | Mkt Cap | 68.50M |
| Vol | 307.54K | Avg Vol | 430.81K | EPS | -1.68 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.35 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.79 | 200-d Avg | 1.08 | 1yr Est | 0.00 |
RNTX News
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pip
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a bioph
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a bioph
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in t
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved thera
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved thera
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a
Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) has earned an average rating of "Hold" from
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analys
AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reducti
Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary F
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (
Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a B
Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient
HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a B
Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds e
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.19) per share which beat the analys
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company")
8 patients enrolled, with additional patients expected in the near termEnrollment initiated in Marc
Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries
REIN THERAPEUTICS, INC.30,000,000 Shares of Common StockWe are selling 30,000,000 shares of our comm
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.11) per share which beat the analys
Shares of Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) traded up 1.6% during trading on F
Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report)'s stock price traded down 0.8% during mid-da
Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 mil
AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha
AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a bioph
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceut